摘要
目的试验将针对慢性胃炎患者实施艾司奥美拉唑肠溶胶囊联合硫糖铝口服混悬液治疗,对比临床应用疗效。方法试验选取2019年6月至2020年5月收治的慢性胃炎患者作为研究对象,对120例参与试验的患者进行客观分组,每组60例。对照组患者采用硫糖铝口服混悬液治疗,观察组则为艾司奥美拉唑肠溶胶囊联合硫糖铝口服混悬液治疗。本次试验需要对患者的疗效结果做出评估,显效指的是患者临床症状消失,在胃镜检查下无胃黏膜慢性炎症表现。有效指的是患者的症状明显缓解,且在胃镜检查下炎症表现好转。无效则是上述要求均未满足,症状可存在加重趋势。此外,对比患者胃镜黏膜积分,可分为0-4分,0分表示未见糜烂黏膜,4分则为普遍存在弥散性糜烂病灶,即得分越高,病情越重。最后,则是对比炎性反应因子水平,如TNF-α、IL-6以及CRP水平。结果从疗效上看,观察组治疗总有效率为95.00%(57/60),对照组为83.33%(50/60),对比具有统计学意义(P <0.05)。在观察患者的胃镜黏膜积分,在治疗后,观察组得分为(0.52±0.09)分,对照组则为(0.81±0.12)分,差异具有统计学意义(P <0.05)。在炎性反应因子水平的对比中,观察组治疗后的TNF-α、IL-6以及CRP水平分别为(14.25±2.96)fmol/L、(11.92±1.58)pg/mL、(5.86±1.12)mg/L,对照组分别为(21.42±2.15)fmol/L、(16.52±1.21)pg/mL、(9.25±1.25)mg/L,即TNF-α、IL-6以及CRP水平上,观察组各项数据指标优于对照组,差异具有统计学意义(t=9.365、10.698、11.417,P均<0.05)。结论采用艾司奥美拉唑肠溶胶囊联合硫糖铝口服混悬液治疗慢性胃炎效果显著,有助于患者病情的康复。
Objective The experiment will implement esomeprazole enteric-coated capsules combined with sucralfate oral suspension for the treatment of patients with chronic gastritis,and compare the clinical efficacy.Methods The trial selected patients with chronic gastritis admitted from June 2019 to May 2020 as the research objects,and objectively grouped 120 patients who participated in the trial,60 cases in each group.The control group was treated with sucralfate oral suspension,and the observation group was treated with esomeprazole enteric-coated capsules combined with sucralfate oral suspension.This trial needs to evaluate the results of the patient’s curative effect.Significantly effective refers to the disappearance of the patient’s clinical symptoms and no chronic inflammation of the gastric mucosa under gastroscopy.Effective means that the patient’s symptoms are significantly relieved,and the inflammation is improved under gastroscopy.Ineffective means that none of the above requirements were met,and the symptoms may have a tendency to worsen.In addition,comparing the gastroscopic mucosal scores of patients,it can be divided into 0 to 4 points.A score of 0 indicates that there is no erosion of the mucosa,and a score of 4 indicates the widespread presence of diffuse erosion lesions,that is,the higher the score,the more severe the disease.Finally,compare the levels of inflammatory response factors,such as TNF-α,IL-6,and CRP levels.Results From the perspective of curative effect,the total effective rate of treatment in the observation group was 95.00%(57/60)and that in the control group was 83.33%(50/60).The comparison was statistically significant(P<0.05).In the observation of patients’gastroscopic mucosal scores,after treatment,the observation group scored(0.52±0.09)points and the control group scored(0.81±0.12)points,the difference was statistically significant(P<0.05).In the comparison of the levels of inflammatory response factors,the levels of TNF-α,IL-6 and CRP in the observation group after treatm
作者
张慧
ZHANG Hui(Second Department of Gastroenterology,Yankuang New Milestone General Hospital,Zoucheng 273500,China)
出处
《中国医药指南》
2021年第19期23-25,共3页
Guide of China Medicine
关键词
慢性胃炎
艾司奥美拉唑肠溶胶囊
硫糖铝口服混悬液
临床疗效
Chronic gastritis
Esomeprazole enteric-coated capsules
Sucralfate oral suspension
Clinical efficacy
